Total Funding
1
Total FundingDebt Financing raised
Growth Score
pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3127484
QSAM Biosciences is a developer of nuclear medicines for the treatment of cancer and related diseases and conditions.
Douglas Baum: Co-Founder, Chief Executive Officer, Director & PresidentPast Role: Central Texas Angel Network, Managing investor- C. Richard Piazza: Executive Chairman & Co-Founder
About the Company
QSAM Biosciences is a developer of nuclear medicines for the treatment of cancer and related diseases and conditions. Its initial technology is Samarium-153 DOTMP, aka CycloSam, a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine space who also developed FDA-approved and
commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation. CycloSam was assigned to IsoTherapeutics Group’s subsidiary, IGL Pharma, Inc.
